Malignant Mesothelioma Clinical Trial
Official title:
Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma (MPM) With or Without Hemithoracic Radiotherapy. A Randomized Multicenter Phase II Trial
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy
x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells
that remain after surgery.
PURPOSE: This randomized phase II trial is studying how well giving pemetrexed disodium
together with cisplatin followed by surgery with or without radiation therapy works in
treating patients with malignant pleural mesothelioma.
OBJECTIVES:
Primary
- Evaluate the short-term outcomes and feasibility of neoadjuvant therapy with pemetrexed
disodium and cisplatin followed by extrapleural pneumonectomy in patients with malignant
pleural mesothelioma.
- Evaluate the long-term outcomes and feasibility of postoperative hemithoracic
radiotherapy in patients with R0 or R1 resection.
Secondary
- Determine the quality of life of these patients.
- Identify predictive and prognostic markers in these patients.
- Determine relapse-free or progression-free survival and overall survival of these
patients.
- Collect tissue and blood from these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
participating center, histology (sarcomatous or other vs epithelial or mixed histology),
nodal status (N0-1 vs N2), and extent of disease (T1-2 vs T3).
- Part 1 (neoadjuvant therapy and surgery): Patients receive pemetrexed disodium IV over
10 minutes and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for 3
courses in the absence of disease progression or unacceptable toxicity. Within 8 weeks
after completion of neoadjuvant therapy, patients without progressive disease undergo
extrapleural pneumonectomy.
- Part 2 : Patients achieving R0 or R1 resection proceed to part 2 of study treatment and
are randomized to 1 of 2 treatment arms. Patients with R2 resection, disease
progression, or symptomatic deterioration after treatment in part 1 are taken off study.
- Arm I (no postoperative radiotherapy): Patients do not undergo radiotherapy.
Quality of life is assessed at baseline and at 6, 10, 16, and 22 weeks after
randomization.
- Arm II (postoperative radiotherapy): Beginning within 10 weeks after surgery,
patients undergo radiotherapy to the hemithoracic region 5 days a week for
approximately 5 weeks in the absence of disease progression or unacceptable
toxicity. Quality of life is assessed at baseline and at 4, 8, 14, and 20 weeks
after initiation of radiotherapy.
Patients undergo blood and tissue collection at registration and surgery for laboratory and
biomarker analysis.
After completion of study treatment, patients are followed periodically for up to 5 years
after surgery.
PROJECTED ACCRUAL: A total of 155 patients will be accrued for this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06057935 -
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
|
Phase 2 | |
Completed |
NCT00075699 -
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 3 | |
Completed |
NCT00821860 -
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
|
Phase 3 | |
Completed |
NCT00004033 -
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT03678350 -
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
|
Phase 1 | |
Recruiting |
NCT02580747 -
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|
Phase 1 | |
Completed |
NCT00398138 -
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
|
Phase 1 | |
Completed |
NCT00019825 -
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
|
Phase 1 | |
Terminated |
NCT00898547 -
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
|
||
Active, not recruiting |
NCT00030459 -
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00004183 -
Capecitabine in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00004254 -
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
|
Phase 2 | |
Completed |
NCT00004920 -
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
|
Phase 3 | |
Completed |
NCT00005636 -
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
|
Phase 3 | |
Completed |
NCT01291420 -
Dendritic Cell Vaccination for Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
Active, not recruiting |
NCT01649024 -
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00513877 -
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00372840 -
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
|
N/A | |
Active, not recruiting |
NCT00253409 -
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
|
N/A |